Biomarker Study of Cholangiocarcinoma

Qinyi Cai

2022

Abstract

Cholangiocarcinoma is a malignant tumor originating from the epithelial cells of the bile duct mucosa in the biliary tract. The incidence of cholangiocarcinoma is increasing day by day. The current diagnostic technology cannot meet the needs of early diagnosis and the prognosis is poor, resulting in high mortality. Therefore, cholangiocarcinoma is known as the "king of cancer". How to effectively diagnose cholangiocarcinoma as soon as possible is of great significance for prolonging the life of patients with cholangiocarcinoma. Based on the diagnosis and treatment of cholangiocarcinoma, this paper summarizes the existing research results and clinical methods, reviews the current research status of biomarkers for cholangiocarcinoma, and looks into the future development of biomarkers.

Paper Citation

in Harvard Style

Cai Q. (2022). Biomarker Study of Cholangiocarcinoma. In Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB, ISBN 978-989-758-595-1, pages 288-294. DOI: 10.5220/0011201800003443

in Bibtex Style

@conference{icbeb22,
author={Qinyi Cai},
title={Biomarker Study of Cholangiocarcinoma},
booktitle={Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB,},
year={2022},
pages={288-294},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0011201800003443},
isbn={978-989-758-595-1},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB,
TI - Biomarker Study of Cholangiocarcinoma
SN - 978-989-758-595-1
AU - Cai Q.
PY - 2022
SP - 288
EP - 294
DO - 10.5220/0011201800003443